Corp Communication News Today

KUALA LUMPUR, Feb 27 — The Ministry of Science, Technology and Innovation (Mosti) will embark on a groundbreaking data-sharing initiative with the Malaysia Technology Expo...

"The US is a superpower, a largest market. Specifically, there are businesses or sectors which are not present at that scale in any other country apart from the US. If you want to buy technology, innovative health care businesses which are there in the US, you have to go to the US market as a part of your diversification strategy."

Mydecine Innovations Group, Inc., is pleased to announce that its subsidiary Mindleap Health a digital health platform and the world’s-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in both The United States Patent and Trademark Office and the Canadian Intellectual Property Office. “As our company continues to innovate … Mydecine Innovations Group, Inc., ( CSE:MYCO ) ( OTC:MYCOF ) ( FSE:0NFA ) ...

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the appointment of Josephine Wu, Founder and CIO at Aionious Management, Ltd., to the Company’s Board of Directors. Josh Bartch, Chairman and CEO of Mydecine, stated, “The Board of Directors welcomes Ms. Josephine Wu … Myde...

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it has received Conditional Approval to migrate and uplist its common shares with the NEO Exchange . Final approval is subject to the Company fulfilling all of NEO’s listing requirements. With the impending...

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: “Facilitating extinction of fear with psilocybin: Model development of biomarkers and mechanisms,” at the University of Maryland School of ...

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has appointed veteran corporate finance and capital markets professional, Gordon Neal to the Board of Directors. Additionally, Dean Ditto has joined the Company as Chief Financial ...

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it has partnered with ProPharma Group, the leading provider of regulatory and compliance services to the pharmaceutical, biotech, and...

Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced today that the Company has partnered with Microdose Psychedelic Insights a leader in B2B psychedelic intelligence, to present a free, three-pa...